This is a preview of subscription content, log in via an institution to check access.
References
Arnold JJ, Sarks SH. Extracts from clinical evidence: age-related macular degeneration. BMJ 2000 Sep 23; 321: 741–44
Fine SL, Berger JW, Maguire MG et al. Age-related macular degeneration. N Engl J Med 2000; 342(7): 483–92
Scott LJ, Goa KL. Verteporfin. Drugs Aging 2000 Feb; 16(2): 139–46
Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative [published erratum appears in Br J Cancer 1995 Jan; 71 (1): 214]. Br J Cancer 1994 May; 69: 833–9
Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999; 117: 1329–45
US Department of Health and Human Services Food and Drug Administration. New Drug Application 21-119. Food and Drug Administration. Available from: URL: http://www.fda.gov [Accessed 2000 Oct 30]
Anonymous. Light-activated agent approved for ocular disorder. Am J Health-Sys Pharm 2000 Jun; 57: 1018, 1021.
Rights and permissions
About this article
Cite this article
Verteporfin photodynamic therapy a first-line option for the leading cause of blindness — age-related macular degeneration. Drugs Ther. Perspect 17, 1–5 (2001). https://doi.org/10.2165/00042310-200117030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200117030-00001